

09/719221

528 Rec'd PCT/PTO 11 DEC 2000

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION

International Office

INTERNATIONAL APPLICATION PUBLISHED ACCORDING TO THE PATENT
COOPERATION TREATY (PCT)

- (51) International patent classification⁶: H04N 5/00 A2
- (11) International publication number: WO 99/65228
- (43) International publication date: December 16, 1999 (12/16/99)
- (21) International file number: PCT/DE99/01652
- (22) International application date: June 7, 1999 (6/7/99)
- (30) Priority data: 198 25 591.8 June 9, 1998 (6/9/98) DE
- (71) Applicant (for all designated countries except US):
JENAPHARM GMBH & CO. KG [DE/DE]; Otto-Schott-Strasse 15, D-
07745 Jena (DE).
-
- (72) Inventors; and
- (75) Inventors/applicants (only for US): HÜBLER, Doris [DE/DE];
No. 12, D-07407 Schmieden (DE). OETTEL, Michael [DE/DE];
Beethovenstrasse 30, D-07743 Jena (DE). SOBEK, Lothar
[DE/DE]; Blochmannstrasse 6, D-07743 Jena (DE). ELGER,
Walter [DE/DE]; Schorlemer Allee 12b, D-14195 Berlin (DE).
AL-MUDHAFFAR, Abdul-Abbas [DE/DE]; S.-Allende-Platz 15, D-
07747 Jena (DE).
- (74) Attorney: LEYBACH, Holger; Jenapharm GmbH & Co. KG, Otto-
Schott-Strasse 15, D-07745 Jena (DE).
- (81) Designated countries: AL, AU, BA, BB, BG, BR, CA, CN, CU,
CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK,
LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL,
TR, TT, UA, US, UZ, VN, YU, ARIPO Patent (GH, GM, KE, LS,
MW, SD, SE, SZ, UG, ZW), Eurasian Patent (AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI
Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN,
TD, TG).

Published:

Without international search report and to be republished
after receipt of the report.

(54) Title: PHARMACEUTICAL COMBINATIONS FOR COMPENSATING FOR A
TESTOSTERONE DEFICIENCY IN MEN WHILE
SIMULTANEOUSLY PROTECTING THE PROSTATE

(57) Abstract

This invention relates to pharmaceutical combinations for
compensating for an absolute and relative testosterone deficiency
in men with simultaneous prophylaxis for the development of a
benign prostatic hyperplasia (BPH) or prostate cancer. The
combinations according to the invention contain a natural or
synthetic androgen in combination with a gestagen, an
antigestagen, an antiestrogen, a GnRH analog, a testosterone-5 α -
reductase inhibitor, an α -andreno-receptor blocker or a
phosphodiesterase inhibitor. In comparison to the combinations
according to the invention, any active ingredient by itself
cannot achieve the desired goal.

FOR INFORMATION ONLY

Codes used for identifying PCT member countries on the head sheets of the publications of international applications according to the PCT.

AL	Albania
AM	Armenia
AT	Austria
AU	Australia
AZ	Azerbaijan
BA	Bosnia-Herzegovina
BB	Barbados
BE	Belgium
BF	Burkina Faso
BG	Bulgaria
BJ	Benin
BR	Brazil
BY	Belarus
CA	Canada
CF	Central African Republic
CG	Congo
CH	Switzerland
CI	Ivory Coast
CM	Cameroon
CN	China
CU	Cuba
CZ	The Czech Republic
DE	Germany
DK	Denmark
EE	Estonia
ES	Spain
FI	Finland
FR	France
GA	Gabon
GB	United Kingdom
GE	Georgia
GH	Ghana
GN	Guinea
GR	Greece
HU	Hungary
IE	Ireland
IL	Israel
IS	Iceland
IT	Italy
JP	Japan
KE	Kenya
KG	Kyrgyzstan
KP	Democratic People's Republic of Korea
KR	Republic of Korea
KZ	Kazakhstan
LC	St. Lucia

LI	Liechtenstein
LK	Sri Lanka
LR	Liberia
LS	Lesotho
LT	Lithuania
LU	Luxembourg
LV	Latvia
MC	Monaco
MD	Republic of Moldova
MG	Madagascar
MK	the former Yugoslavian Republic of Macedonia
ML	Mali
MN	Mongolia
MR	Mauritania
MW	Malawi
MX	Mexico
NE	Niger
NL	The Netherlands
NO	Norway
NZ	New Zealand
PL	Poland
PT	Portugal
RO	Romania
RU	Russian Federation
SD	Sudan
SE	Sweden
SG	Singapore
SI	Slovenia
SK	Slovakian Republic
SN	Senegal
SZ	Swaziland
TD	Chad
TG	Togo
TJ	Tajikistan
TM	Turkmenistan
TR	Turkey
TT	Trinidad and Tobago
UA	The Ukraine
UG	Uganda
US	United States of America
UZ	Uzbekistan
VN	Vietnam
YU	Yugoslavia
ZW	Zimbabwe